Plain-English translation of NCT06072898 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Depressive Disorder research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This research trial is testing whether —a psychedelic compound—produces measurable changes in how your brain networks communicate, especially in areas related to mood and depression. Researchers will use MRI brain scans to see if the medication shifts brain activity in ways that might help with depression. The study aims to understand whether these brain changes happen specifically because of the medication, or whether other factors (like the supportive therapy you'll receive) play a role.
Standard antidepressant medications don't work well for everyone, and doctors are looking for new approaches. Early research suggests this medication might help depression by changing brain activity in mood-related regions, but we need more rigorous evidence to understand exactly how and why this happens.
You likely qualify if…
You likely don't qualify if…
You will attend two treatment sessions, roughly spaced apart. At each session, you'll take an oral medication (either the study medication or a placebo, depending on which group you're randomly assigned to), then have an MRI brain scan while the medication is active. After the scan, you'll receive supportive counseling from a therapist. A caregiver must be present to monitor you for 24 hours after each session. The trial also includes screening visits and follow-up assessments to check your mood and overall wellbeing.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
Canada